Recurrent HCV after liver transplantation - Mechanisms, assessment and therapy

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 12, 2014, Pages 710-721

  Joshi, Deepak ^a   Pinzani, Massimo ^b   Carey, Ivana ^a   Agarwal, Kosh ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; COLLAGEN TYPE 3; CORTICOSTEROID; CYCLOPHILIN B; CYCLOSPORIN A; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY CD3; OKT 3; TACROLIMUS;

COMORBIDITY; ELASTOGRAPHY; HEMATOLOGICAL PARAMETERS; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE ELASTOGRAPHY; MIXED INFECTION; ORGAN DONOR; OUTCOME ASSESSMENT; PLATELET RATIO INDEX; PRIORITY JOURNAL; QUALITY CONTROL; RECURRENT DISEASE; RETRANSPLANTATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS PATHOGENESIS; ADVERSE EFFECTS; BIOPSY; FIBROSIS; GRAFT SURVIVAL; HEPATITIS C, CHRONIC; LIVER; METABOLISM; PATHOLOGY; RISK FACTOR; STELLATE CELL;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOPSY; FIBROSIS; GRAFT SURVIVAL; HEPATIC STELLATE CELLS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS;

EID: 84927174572     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.114     Document Type: Review

References (184)

1. Sung, V. M. et al. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J. Virol. 77, 2134-2146 (2003).
2. Schulze-Krebs, A. et al. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 129, 246-258 (2005).
3. Biron, C. A., Byron, K. S. & Sullivan, J. L. Severe herpes virus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320, 1731-1735 (1989).
4. Feray, C. et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J. Clin. Invest. 89, 1361-1365 (1992).
5. Gane, E. J. et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 110, 167-177 (1996).
6. Garcia-Retortillo, M. et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 35, 680-687 (2002).
7. Yilmaz, N. et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl. 13, 975-983 (2007).
8. Prieto, M. et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 29, 250-256 (1999).
9. Rosen, H. R. et al. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 65, 1178-1182 (1998).
10. Rosen, H. R. et al. Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation 62, 1773-1776 (1996).
11. Gane, E. J. et al. Long-term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med. 334, 815-820 (1996).
12. Pelletier, S. J. et al. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl. 6, 44-53 (2000).
13. Firpi, R. J. et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl. 10, 1240-1247 (2004).
14. Berenguer, M. et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J. Hepatol. 32, 673-684 (2000).
15. Wali, M., Harrison, R. F., Gow, P. J. & Mutimer, D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 51, 248-252 (2002).
16. Sebagh, M. et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 37, 1293-1301 (2003).
17. Belli, L. S. et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl. 13, 733-740 (2007).
18. Neumann, U. P. et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J. Hepatol. 41, 830-836 (2004).
19. Baiocchi, L. et al. Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease. Am. J. Transplant. 8, 673-678 (2008).
20. Berenguer, M. et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 32, 852-858 (2000).
21. Pruthi, J. et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl. 7, 811-815 (2001).
22. Sanchez-Fueyo, A. et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 73, 56-63 (2002).
23. Zekry, A. et al. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl. 9, 339-347 (2003).
24. Thuluvath, P. J., Krok, K. L., Segev, D. L. & Yoo, H. Y. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl. 13, 719-724 (2007).
25. Forman, L. M., Lewis, J. D., Berlin, J. A., Feldman, H. I. & Lucey, M. R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122, 889-896 (2002).
26. Mutimer, D. J. et al. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation 81, 7-14 (2006).
27. Ghobrial, R. M. et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann. Surg. 234, 384-393 (2001).
28. Busuttil, R. W. et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann. Surg. 241, 905-916 (2005).
29. Bahra, M. et al. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation 83, 351-353 (2007).
30. Roche, B. et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 14, 1766-1777 (2008).
31. Picciotto, F. P. et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J. Hepatol. 46, 459-465 (2007).
32. Kato, N. et al. Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J. Virol. 68, 4776-4784 (1994).
33. Sanchez-Fueyo, A. et al. Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation. J. Med. Virol. 65, 266-275 (2001).
34. Hayashi, J. et al. Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology 25, 697-701 (1997).
35. Ferenbach, D. A., Haydon, G. H., Rae, F., Malcomson, R. D. & Harrison, D. J. Alteration in mRNA levels of Fas splice variants in hepatitis C-infected liver. J. Pathol. 183, 299-304 (1997).
36. Pianko, S., Patella, S., Ostapowicz, G., Desmond, P. & Sievert, W. Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J. Viral Hepat. 8, 406-413 (2001).
37. Erickson, A. L. et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15, 883-895 (2001).
38. Bataller, R., Paik, Y. H., Lindquist, J. N., Lemasters, J. J. & Brenner, D. A. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 126, 529-540 (2004).
39. Berenguer, M. & Schuppan, D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J. Hepatol. 58, 1028-1041 (2013).
40. Mazzocca, A. et al. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J. Biol. Chem. 280, 11329-11339 (2005).
41. Sakata, K. et al. HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type I receptor. Sci. Rep. 3, 3243 (2013).
42. Schuppan, D. & Afdhal, N. H. Liver cirrhosis. Lancet 371, 838-851 (2008).
43. Friedman, S. L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655-1669 (2008).
44. Meng, F. et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143, 765-776 (2012).
45. Wynn, T. A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199-210 (2008).
46. Seki, E. et al. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat. Med. 13, 1324-1332 (2007).
47. Schuppan, D., Krebs, A., Bauer, M. & Hahn, E. G. Hepatitis C and liver fibrosis. Cell Death Differ. 10 (Suppl. 1), S59-S67 (2003).
48. Safadi, R. & Friedman, S. L. Hepatic fibrosis-role of hepatic stellate cell activation. MedGenMed 4, 27 (2002).
49. Gawrieh, S. et al. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl. 11, 1207-1213 (2005).
50. Cisneros, L. et al. Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C. Liver Transpl. 13, 1017-1027 (2007).
51. Bedossa, P., Dargere, D. & Paradis, V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38, 1449-1457 (2003).
52. Standish, R. A., Cholongitas, E., Dhillon, A., Burroughs, A. K. & Dhillon, A. P. An appraisal of the histopathological assessment of liver fibrosis. Gut 55, 569-578 (2006).
53. Feliu, A., Gay, E., Garcia-Retortillo, M., Saiz, J. C. & Forns, X. Evolution of hepatitis C virus quasispecies immediately following liver transplantation. Liver Transpl. 10, 1131-1139 (2004).
54. McCaughan, G. W. & Bowen, D. G. Pathogenesis of cholestatic hepatitis C. J. Hepatol. 54, 392-394 (2011).
55. Gopal, D. V. & Rosen, H. R. Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl. 9, 348-353 (2003).
56. Zekry, A. et al. Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl. 8, 292-301 (2002).
57. Doughty, A. L., Painter, D. M. & McCaughan, G. W. Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus. J. Hepatol. 32, 126-134 (2000).
58. Lyra, A. C. et al. Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology 123, 1485-1493 (2002).
59. Smith, P. D., Saini, S. S., Raffeld, M., Manischewitz, J. F. & Wahl, S. M. Cytomegalovirus induction of tumor necrosis factor-alpha by human monocytes and mucosal macrophages. J. Clin. Invest. 90, 1642-1648 (1992).
60. Tilg, H., Vogel, W., Herold, M., Aulitzky, W. E. & Huber, C. Cachexia and tumour necrosis factor-α in cytomegalovirus infection. J. Clin. Pathol. 44, 519-520 (1991).
61. Granot, E., Shouval, D. & Ashur, Y. Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients. Mediators Inflamm. 10, 253-258 (2001).
62. Ballardini, G. et al. Hepatocellular expression of HLA-A, B, C molecules predicts primary response to interferon in patients with chronic hepatitis C. Am. J. Clin. Pathol. 102, 746-751 (1994).
63. Rosen, H. R. et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 64, 721-726 (1997).
64. Safadi, R. et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 127, 870-882 (2004).
65. Joshi, D., O'Grady, J., Dieterich, D., Gazzard, B. & Agarwal, K. Increasing burden of liver disease in patients with HIV infection. Lancet 377, 1198-1209 (2011).
66. Antonini, T. M. et al. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. Am. J. Transplant. 11, 1686-1695 (2011).
67. Terrault, N. A. et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 18, 716-726 (2012).
68. Miro, J. M. et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am. J. Transplant. 12, 1866-1876 (2012).
69. Duclos-Vallee, J. C. et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 47, 407-417 (2008).
70. Garba, M. L., Pilcher, C. D., Bingham, A. L., Eron, J. & Frelinger, J. A. HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8+ T cells. J. Immunol. 168, 2247-2254 (2002).
71. Balagopal, A. et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 135, 226-233 (2008).
72. Glassner, A. et al. Impaired CD4+ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. J. Hepatol. 59, 427-433 (2013).
73. Bruno, R. et al. gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut 59, 513-520 (2010).
74. Taner, C. B. et al. Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus. Liver Transpl. 17, 641-649 (2011).
75. Berenguer, M. et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 36, 202-210 (2002).
76. Rayhill, S. C. et al. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 84, 331-339 (2007).
77. Khapra, A. P. et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl. 12, 1496-1503 (2006).
78. Machicao, V. I. et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 77, 84-92 (2004).
79. Lake, J. R. et al. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am. J. Transplant. 5, 549-557 (2005).
80. Berenguer, M. et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 38, 34-41 (2003).
81. Baltz, A. C. & Trotter, J. F. Living donor liver transplantation and hepatitis C. Clin. Liver Dis. 7, 651-665 (2003).
82. Linton, P. J. & Dorshkind, K. Age-related changes in lymphocyte development and function. Nat. Immunol. 5, 133-139 (2004).
83. Pawelec, G. et al. Human immunosenescence: is it infectious? Immunol. Rev. 205, 257-268 (2005).
84. Hoare, M. et al. CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection. J. Hepatol. 53, 252-260 (2010).
85. Foxton, M. R. et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am. J. Transplant. 6, 1922-1929 (2006).
86. Veldt, B. J. et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am. J. Transplant. 9, 1406-1413 (2009).
87. Paradis, V. et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 34, 738-744 (2001).
88. Durante-Mangoni, E. et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-α in chronic hepatitis C patients. Aliment. Pharmacol. Ther. 24, 1349-1357 (2006).
89. Charlton, M. & Seaberg, E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl. Surg. 5, S107-S114 (1999).
90. Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M. & Shimotohno, K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38, 1282-1288 (2003).
91. Firpi, R. J. et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig. Dis. Sci. 55, 196-203 (2010).
92. Watashi, K. et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell 19, 111-122 (2005).
93. Hirano, K. et al. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl. 14, 292-298 (2008).
94. Nakagawa, M. et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 129, 1031-1041 (2005).
95. Berenguer, M., Royuela, A. & Zamora, J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl. 13, 21-29 (2007).
96. Levy, G. et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl. 12, 1464-1472 (2006).
97. Berenguer, M. et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 90, 1204-1209 (2010).
98. Akselband, Y., Harding, M. W. & Nelson, P. A. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. Transplant. Proc. 23, 2833-2836 (1991).
99. Neef, M., Ledermann, M., Saegesser, H., Schneider, V. & Reichen, J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J. Hepatol. 45, 786-796 (2006).
100. McKenna, G. J. et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am. J. Transplant. 11, 2379-2387 (2011).
101. Manousou, P. et al. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut 63, 1005-1013 (2014).
102. Lange, C. M. et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J. Hepatol. 55, 322-327 (2011).
103. Eurich, D. et al. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl. 17, 289-298 (2011).
104. Charlton, M. R. et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53, 317-324 (2011).
105. Eurich, D. et al. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 93, 644-649 (2012).
106. Duarte-Rojo, A. et al. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation 94, 197-203 (2012).
107. Veldt, B. J. et al. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am. J. Transplant. 12, 737-744 (2012).
108. Berres, M. L. et al. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. Hepatology 53, 596-603 (2011).
109. Cisneros, E. et al. Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860. Transplantation 94, 275-280 (2012).
110. Gane, E. J. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 14 (Suppl. 2), S36-S44 (2008).
111. Ghabril, M., Dickson, R. & Wiesner, R. Improving outcomes of liver retransplantation: an analysis of trends and the impact of Hepatitis C infection. Am. J. Transplant. 8, 404-411 (2008).
112. McCashland, T. et al. Retransplantation for hepatitis C: results of a U. S. multicenter retransplant study. Liver Transpl. 13, 1246-1253 (2007).
113. Bahra, M. et al. Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C. Transpl. Int. 20, 771-778 (2007).
114. Andres, A. et al. A score predicting survival after liver retransplantation for hepatitis C virus cirrhosis. Transplantation 93, 717-722 (2012).
115. Bain, V. G. et al. A multicentre study of the usefulness of liver biopsy in hepatitis C. J. Viral Hepat. 11, 375-382 (2004).
116. Ishak, K. et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 22, 696-699 (1995).
117. Westin, J., Lagging, L. M., Wejstal, R., Norkrans, G. & Dhillon, A. P. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 19, 183-187 (1999).
118. Samonakis, D. N. et al. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl. 13, 1305-1311 (2007).
119. Blasco, A. et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 43, 492-499 (2006).
120. Calvaruso, V. et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 49, 1236-1244 (2009).
121. Manousou, P. et al. Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. Liver Transpl. 17, 178-188 (2011).
122. Manousou, P. et al. Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation. J. Hepatol. 58, 962-968 (2013).
123. Shaheen, A. A. & Myers, R. P. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 46, 912-921 (2007).
124. Lin, Z. H. et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 53, 726-736 (2011).
125. Toniutto, P. et al. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation. J. Gastroenterol. Hepatol. 22, 1904-1908 (2007).
126. Benlloch, S. et al. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. Liver Transpl. 11, 456-462 (2005).
127. Pungpapong, S. et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 19, 690-700 (2013).
128. Carrion, J. A. et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 138, 147-158 (2010).
129. Cross, T. J. et al. A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation. J. Viral Hepat. 17, 640-649 (2010).
130. Cross, T. J. et al. King's Score: an accurate marker of cirrhosis in chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 21, 730-738 (2009).
131. Beckebaum, S. et al. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients. Transplantation 89, 983-993 (2010).
132. Rigamonti, C. et al. Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation. Gut 57, 821-827 (2008).
133. Carrion, J. A. et al. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 51, 23-34 (2010).
134. Harada, N. et al. Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation. Transplantation 85, 69-74 (2008).
135. Manduca, A. et al. Magnetic resonance elastography: non-invasive mapping of tissue elasticity. Med. Image Anal. 5, 237-254 (2001).
136. Rouviere, O. et al. MR elastography of the liver: preliminary results. Radiology 240, 440-448 (2006).
137. Talwalkar, J. A. et al. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 47, 332-342 (2008).
138. Lee, V. S. et al. Magnetic resonance elastography and biomarkers to assess fibrosis from recurrent hepatitis C in liver transplant recipients. Transplantation 92, 581-586 (2011).
139. van Rooij, E. & Olson, E. N. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J. Clin. Invest. 117, 2369-2376 (2007).
140. Joshi, D. et al. Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation. Liver Transpl. 19, 383-394 (2013).
141. Gehrau, R. C. et al. MicroRNA signature at the time of clinical HCV recurrence associates with aggressive fibrosis progression post-liver transplantation. Am. J. Transplant. 13, 729-737 (2013).
142. Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685-1694 (2013).
143. Berenguer, M. Natural history of recurrent hepatitis C. Liver Transpl. 8, S14-S18 (2002).
144. Curry, M. P. et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation [abstract 213]. Hepatology 58 (Suppl. 1), 314A (2013).
145. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 55, 245-264 (2011).
146. Everson, G. T. et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42, 255-262 (2005).
147. Everson, G. T. et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 57, 1752-1762 (2013).
148. Poordad, F. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195-1206 (2011).
149. Jacobson, I. M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405-2416 (2011).
150. Bacon, B. R. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207-1217 (2011).
151. Zeuzem, S. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417-2428 (2011).
152. Hezode, C. et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J. Hepatol. 59, 434-441 (2013).
153. Sulkowski, M. S. et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 370, 211-221 (2014).
154. Abbvie. AbbVie completes largest phase III program of an all oral interferon-free therapy for the treatment of hepatitis C genotype 1 [online], http://abbvie.mediaroom.com/2014-01-31-AbbVie-Completes-Largest-Phase-III-Program-of-an-All-Oral-Interferon-Free-Therapy-for-the-Treatment-of-Hepatitis-C-Genotype-1 (2014).
155. Jacobson, I. M. et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study [abstract]. Hepatology 58 (Suppl. 1), LB-3 (2013).
156. Berenguer, M. et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am. J. Transplant. 8, 679-687 (2008).
157. Berenguer, M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J. Hepatol. 49, 274-287 (2008).
158. Xirouchakis, E. et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J. Viral Hepat. 15, 699-709 (2008).
159. Calmus, Y. et al. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin. J. Hepatol. 57, 564-571 (2012).
160. Castells, L. et al. Combined treatment with pegylated interferon (α-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J. Hepatol. 43, 53-59 (2005).
161. Oton, E. et al. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. Am. J. Transplant. 6, 2348-2355 (2006).
162. Hanouneh, I. A. et al. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl. 14, 53-58 (2008).
163. Berenguer, M. et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl. 15, 738-746 (2009).
164. Garg, V. et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 54, 20-27 (2011).
165. Coilly, A. et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob. Agents Chemother. 56, 5728-5734 (2012).
166. Charlton, M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents-a potentially lethal cocktail. Hepatology 54, 3-5 (2011).
167. Coilly, A. et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J. Hepatol. 60, 78-86 (2014).
168. Stravitz, R. T. et al. Higher sustained virologic response (SVR-12) achievable in liver transplant (LT) recipients with hepatitis C (HCV) treated with protease inhibitor (PI) triple therapy (TT) [abstract 461]. Hepatology 58 (Suppl. 1), 429A (2013).
169. Fontana, R. J. et al. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl. 18, 1053-1059 (2012).
170. Fontana, R. et al. First ever successful use of daclatasvir and GS-7977, an interferon-free oral regimen in a liver transplant recipient with severe recurrent hepatitis C [abstract 694]. Hepatology 56 (Suppl. 1), 524A (2012).
171. Kwo, P. Y. & Tector, A. J. Oral direct-acting antiviral therapy to prevent reinfection of the liver graft after liver transplantation for hepatitis C virus-related cirrhosis. Liver Transpl. 19, 780-781 (2013).
172. Charlton, M. R. et al. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective, multicenter study [abstract]. Hepatology 58 (Suppl. 1), LB-2 (2013).
173. Forns, X. et al. Initial evaluation of the sofosbuvir compassionate use program for patients with severe recurrent HCV following liver transplantation [abstract 1084]. Hepatology 58 (Suppl. 1), 732A (2013).
174. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01687270 (2014).
175. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01938430 (2014).
176. Gane, E. J. et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A Inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 146, 736-743 (2014).
177. Baron, P. W. et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl. 6, 407-412 (2000).
178. Cameron, A. M. et al. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann. Surg. 244, 563-571 (2006).
179. Watt, K. D., Lyden, E. R., Gulizia, J. M. & McCashland, T. M. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl. 12, 134-139 (2006).
180. Berenguer, M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl. 9, S44-S47 (2003).
181. Brandman, D. et al. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl. 17, 1380-1386 (2011).
182. Maluf, D. G., Edwards, E. B., Stravitz, R. T. & Kauffman, H. M. Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients. Liver Transpl. 15, 592-599 (2009).
183. Manez, R. et al. The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation. Transplantation 59, 640-642 (1995).
184. Pereira, B. J. & Levey, A. S. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int. 51, 981-999 (1997).